No Data
No Data
Express News | Alpha Cognition Secures Additional U.S. Patent for Zunveyl (Benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s Disease
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (Benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's Disease
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
Alpha Cognition Expands Commercial and Medical Teams With Key Leadership Hires to Support the Launch of ZUNVEYL
China Medical System Signs License Deal With Alpha Cognition for Alzheimer's Drug
Alpha Cognition, China Medical System Enter Exclusive Zunveyl Licensing Pact